Business
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash., January 06, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":334,"url":"https://media.zenfs.com/en/business-wire.com/da76636b2f15111a0384b5ebda2f0587"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WJsV5zXCOWPsTV6R.TXTbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/da76636b2f15111a0384b5ebda2f0587","width":480,"height":334}},"lazy":false},{"type":"text","content":"BOTHELL, Wash., January 06, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.","length":344,"tagName":"p"},{"type":"text","content":"Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.","length":242,"tagName":"p"},{"type":"text","content":"About Immunome, Inc.","length":20,"tagName":"p"},{"type":"text","content":"Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.","length":699,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Investor Contact Max RosettChief Financial [email protected]","length":75,"tagName":"p"}]